These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 33750817)

  • 1. Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease.
    Wang J; Dai M; Fu Q; Chen S
    Sci Rep; 2021 Mar; 11(1):5459. PubMed ID: 33750817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
    Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
    Fattizzo B; Levati G; Cassin R; Barcellini W
    Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
    Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M
    Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag for use in children with immune thrombocytopenia.
    Kim TO; Despotovic J; Lambert MP
    Blood Adv; 2018 Feb; 2(4):454-461. PubMed ID: 29487060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag in severe immune thrombocytopenia secondary to connective tissue disease: a report of 17 patients and literature review.
    Li W; Wang D; Ma L; Zhu Y; Wang F; Hua B; Wang H; Feng X
    Clin Rheumatol; 2023 May; 42(5):1451-1457. PubMed ID: 36593363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
    Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
    Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
    N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
    Özdemirkıran F; Payzın B; Kiper HD; Kabukçu S; Akgün Çağlıyan G; Kahraman S; Sevindik ÖG; Ceylan C; Kadıköylü G; Şahin F; Keskin A; Arslan Ö; Özcan MA; Kabukçu G; Görgün G; Bolaman Z; Büyükkeçeci F; Bilgir O; Alacacıoğlu İ; Vural F; Tombuloğlu M; Gökgöz Z; Saydam G
    Turk J Haematol; 2015 Dec; 32(4):323-8. PubMed ID: 25914025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
    Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
    Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
    Zhang Y; Kolesar JM
    Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.
    Wang X; Liu X; Wang L; Wang JY; Li A
    Blood Coagul Fibrinolysis; 2019 Mar; 30(2):71-74. PubMed ID: 30720490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.
    Cook L; Cooper N
    Drug Des Devel Ther; 2010 Jul; 4():139-45. PubMed ID: 20689640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.